Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 5074 multiple-dose study in mild cognitive impairment
2010-024270-19Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Itanapraced in Mild Cognitive Impairment (MCI) (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Maximum tolerated dose of CHF 5074 and Safety and tolerability. Started Sep 2011; status: completed.
02
Drugs
Itanapraced
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2010-024270-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024270-19.